Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://sitecurious.com
Are you over 18 and want to see adult content?
A complete backup of https://jillcunniff.com
Are you over 18 and want to see adult content?
A complete backup of https://thecraftingnook.com
Are you over 18 and want to see adult content?
A complete backup of https://recessframework.org
Are you over 18 and want to see adult content?
A complete backup of https://libeskind.com
Are you over 18 and want to see adult content?
A complete backup of https://patheon.com
Are you over 18 and want to see adult content?
A complete backup of https://bankera.com
Are you over 18 and want to see adult content?
A complete backup of https://splendicity.com
Are you over 18 and want to see adult content?
A complete backup of https://iti-germany.de
Are you over 18 and want to see adult content?
A complete backup of https://lookseek.com
Are you over 18 and want to see adult content?
A complete backup of https://arzak.info
Are you over 18 and want to see adult content?
A complete backup of https://report-d.de
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of www.telam.com.ar/notas/202002/436086-vecinos-de-villa-crespo-protestan-contra-el-estadio-movistar-arena-ant
Are you over 18 and want to see adult content?
A complete backup of www.unian.net/lite/holidays/10892588-1-marta-2020-kakoy-segodnya-prazdnik-primety-i-imeninniki-chto-segodny
Are you over 18 and want to see adult content?
A complete backup of www.hln.be/showbizz/tom-waes-vindt-advies-van-maggie-de-block-overdreven-ik-kom-na-3-weken-thuis-en-mag-nie
Are you over 18 and want to see adult content?
A complete backup of www.tgcom24.mediaset.it/rubriche/speciale-amarcord/otto-anni-fa-ci-lasciava-lucio-dalla-rivediamolo-ai-tele
Are you over 18 and want to see adult content?
A complete backup of www.storm.mg/article/2348593
Are you over 18 and want to see adult content?
Text
BLOOD
Note: In response to the threat of COVID-19, the Blood editorial office has temporarily suspended use of our headquarters. Journal operations still continue, but for the quickest response to any query or request please email the editorial office at editorial@hematology.org rather thanBLOOD
Note: In response to the threat of COVID-19, the Blood editorial office has temporarily suspended use of our headquarters. Journal operations still continue, but for the quickest response to any query or request please email the editorial office at editorial@hematology.org rather thanBLOOD
Note: In response to the threat of COVID-19, the Blood editorial office has temporarily suspended use of our headquarters. Journal operations still continue, but for the quickest response to any query or request please email the editorial office at editorial@hematology.org rather thanBLOOD
Note: In response to the threat of COVID-19, the Blood editorial office has temporarily suspended use of our headquarters. Journal operations still continue, but for the quickest response to any query or request please email the editorial office at editorial@hematology.org rather thanBLOOD
Note: In response to the threat of COVID-19, the Blood editorial office has temporarily suspended use of our headquarters. Journal operations still continue, but for the quickest response to any query or request please email the editorial office at editorial@hematology.org rather thanBLOOD
Note: In response to the threat of COVID-19, the Blood editorial office has temporarily suspended use of our headquarters. Journal operations still continue, but for the quickest response to any query or request please email the editorial office at editorial@hematology.org rather thanBLOOD
Note: In response to the threat of COVID-19, the Blood editorial office has temporarily suspended use of our headquarters. Journal operations still continue, but for the quickest response to any query or request please email the editorial office at editorial@hematology.org rather than Skip to Main ContentAdvertisement
__
Close
* Blood
* Blood Advances
* Hematology
* ASH-SAP
* ASH Clinical News
* The Hematologist
* International__
* Blood Chinese Edition * Blood Japanese Edition * Blood Italian Edition * Blood Latin America Edition * Blood Spanish Edition* ASH__
* ASH Home
* Research
* Education
* Advocacy
* Meetings
* Publications
* ASH Store
Cart __ _User
Tools_
Cart __
Sign In __
_Search_
nav search search input Search input auto suggest search filter All ContentAll JournalsBloodSearch
_Toggle Menu_Menu
* Issues__
* Current Issue
* All Issues
* First edition
* Abstracts__
* 2020 Annual Meeting * 2020 Late Breaking * 2019 Annual Meeting * 2019 Late Breaking * 2018 Annual Meeting * All Meeting Abstracts* Collections__
* Collections
* Special Collections* Multimedia
* Alerts
* Author Center__
* Submit
* Author Guide
* Style Guide
* Why Submit to Blood?* About__
* About Blood
* Editorial Board and Staff* Subscriptions
* Public Access
* Copyright
* Alerts
* Blood Classifieds
Skip Nav DestinationCurrent Issue
Volume 137,
Issue 22,
June 3, 2021
View This Issue
ISSUE HIGHLIGHTS * Cryo-EM structures of factors V and Va * Reducing lenalidomide for myeloma in older patients * Clonal evolution of FLT3-ITD AML treated with midostaurin * Cell-free mitochondrial DNA in SCD * Review: lymphocytes regulating bone marrow function * Quality of life in afibrinogenemia * _Blood_ Podcast, Season 2, Episode 22Latest in
Blood
Free Articles Simultaneous occurrence of KSHV-associated malignancies in a patient affected by HIV Emanuela Vaccher; Antonino Carbone DOI: 10.1182/blood.2021011649 ViewAll Free Articles
Plenary Papers Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma Sarah Haebe; Tanaya Shree; Anuja Sathe; Grady Day; Debra K. Czerwinski; Susan M. Grimes; HoJoon Lee; Michael S. Binkley; Steven R. Long; Brock Martin; Hanlee P. Ji; Ronald Levy DOI: 10.1182/blood.2020009855 View All Plenary Papers First Edition Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34+ cells in vitro and in vivo Nikoletta Psatha; Aphrodite Georgakopoulou; Chang Li; Vivek Nandakumar; Grigorios Georgolopoulos; Reyes Acosta; Kiriaki Paschoudi; Jemma Nelson; Daniel Raymond Chee; Anastasia Athanasiadou; Anastasia Kouvatsi; Alister Funnell; André Lieber; Evangelia Yannaki; Thalia Papayannopoulou DOI: 10.1182/blood.2020010020 View All First EditionArticles
Clinical Trials and Observations Durable Remissions Following Combined Targeted Therapy in Patients with CLL Harboring TP53 Deletions and/orMutations
Paula Cramer; Eugen Tausch; Julia von Tresckow; Adam Giza; Sandra Robrecht; Christof Schneider; Moritz Fürstenau; Petra Langerbeins; Othman Al-Sawaf; Benedikt W. Pelzer; Anna Maria Fink; Kirsten Fischer; Clemens-Martin Wendtner; Barbara Eichhorst; Michael Kneba; Stephan Stilgenbauer; Michael Hallek DOI: 10.1182/blood.2020010484 View All Clinical Trials and ObservationsAdvertisement
Featured Content
BLOOD PODCAST: SEASON 2, EPISODE 22 In this week’s episode we will review a study in sickle cell disease patients reporting abnormal retention of mitochondria in circulating red cells and elevated mitochondrial DNA in plasma, learn more about the fate of _FLT3-ITD_ clones in AML patients treated with midostaurin, and look at a study showing, for the first time, that selected elderly patients with newly diagnosed multiple myeloma benefit from modification of standard myeloma treatment based on thelevel of frailty.
__DOSE/SCHEDULE-ADJUSTED RD-R VS CONTINUOUS RD FOR ELDERLY, INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA Optimizing outcomes for older patients with multiple myeloma requires achieving the right balance between efficacy and toxicity during ongoing first-line therapy. Larocca and colleagues report a randomized trial with patients with intermediate fitness, comparing standard continuous lenalidomide-dexamethasone (Rd) with a modified regimen (Rd-R) that omits steroids after 9 months and reduces the dose of lenalidomide. The modified regimen delivers similar survival outcomes with less toxicity and offers a new alternative standard for a subgroup of older patients. CLONAL EVOLUTION OF ACUTE MYELOID LEUKEMIA WITH _FLT3_-ITD MUTATION UNDER TREATMENT WITH MIDOSTAURIN Addition of the multikinase inhibitor midostaurin to induction chemotherapy improves outcomes in _FLT3_-ITD–mutated acute myeloid leukemia (AML), but relapse remains common. By studying the mutational profiles of samples from randomized trials with and without midostaurin added to chemotherapy, Schmalbrock et al reveal that relapsed leukemia displays increased heterogeneity, implying multiple mechanisms for resistance. With midostaurin treatment, AML is less likely to be _FLT3_-ITD positive at relapse and more likely to be driven by emergent activating mutations in other growth factorpathways.
CRYO-EM STRUCTURES OF HUMAN COAGULATION FACTORS V AND VA Ruben et al present detailed structures of coagulation factor V (FV) and FVa generated through cryo-electron microscopy (cryo-EM). This study provides unprecedented structural detail on conformational changes in FV upon its activation. These changes control not only its ability to enhance coagulation but also how it is regulated anddegraded.
CLINICAL PHENOTYPE, FIBRINOGEN SUPPLEMENTATION, AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITHAFIBRINOGENEMIA Congenital afibrinogenemia is a very rare autosomal recessive bleeding disorder, with manifestations ranging from minimal bleeding to life-threatening hemorrhage and thrombosis. Casini and colleagues report an international cross-sectional study of 204 patients focusing on the clinical phenotype, quality of life, and management strategies, including prophylaxis with fibrinogen concentrates orcryoprecipitates.
CIRCULATING MITOCHONDRIAL DNA IS A PROINFLAMMATORY DAMP IN SICKLECELL DISEASE
Tumburu et al report abnormal retention of mitochondria in circulating erythrocytes in sickle cell disease and the presence of mitochondrial DNA (mtDNA) in plasma. Cell-free mtDNA is disproportionately hypomethylated, triggers formation of neutrophil extracellular traps, and acts as a damage-associated molecular pattern (DAMP) in patients. This report adds insight to the complex processes by which sickle erythrocytes can increase inflammation beyond the damage caused to thevessel wall.
Advertisement
* Current Issue
* First edition
* All Issues
* Collections
* Abstracts
* Authors
* Submit to Blood
* About Blood
* Subscriptions
* Public Access
* Permissions
* Alerts
* Contact Us
* Blood Classifieds
* Advertising in Blood * Terms and ConditionsASH PUBLICATIONS
* _Blood_
* _Blood Advances_
* _Hematology, ASH Education Program_ * _ASH Clinical News_* _ASH-SAP_
* _The Hematologist_ AMERICAN SOCIETY OF HEMATOLOGY* ASH Home
* Research
* Education
* Advocacy
* Meetings
* Publications
* ASH Store
Copyright ©2020 by American Society of Hematology* Privacy Policy
* Cookie Policy
* Terms of Use
* Contact Us
_Close Modal_
_Close Modal_
THIS FEATURE IS AVAILABLE TO SUBSCRIBERS ONLY Sign In or Create an Account_Close Modal_
_Close Modal_
Advertisement
X
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0